Western Australia’s biomedical sector, a growing field encompassing biotechnology, medical technology, and agricultural technology, is gaining fresh momentum through a state initiative aimed at amplifying local companies’ presence on the national and global stage. The Market Access Grant Scheme (MAGS), now in its third funding round, has allocated $100,000 to help WA biomedical companies connect with investors, partners, and global leaders in the life sciences industry. This programme, championed by the Cook Government, supports eligible WA companies with grants of up to $5,000 each, designed to offset travel costs for major conferences and industry events.
With the biomedical sector continually advancing, support from MAGS opens new avenues for WA companies to expand their reach. The scheme helps these companies participate in significant industry events such as the AusBiotech and AusBioInvest conferences, two major Australian platforms for the biotech sector. This year’s AusBiotech conference, held in Melbourne, is set to host over 1,500 delegates from around the world, making it a golden opportunity for WA’s biomedical innovators to present their capabilities. Leading the delegation of 20 companies and organisations from WA is Medical Research Minister Stephen Dawson, who brings with him representatives from both the Department of Jobs, Tourism, Science and Innovation, and the WA Department of Health. This effort to elevate the visibility of WA’s medical life sciences not only puts the state on the map but also encourages cross-sector collaboration and investment opportunities that could have long-term benefits.
In the broader scope of WA’s biomedical sector, MAGS plays a critical role in supporting companies at a stage where international exposure could make all the difference. Since its inception, the scheme has provided over $170,000 in grants to 39 companies, making it possible for WA’s innovators to explore markets abroad and connect with key players globally. The grants themselves cover a sizeable portion of travel costs, with the requirement that businesses contribute at least 20 per cent of the expenses, ensuring that companies have a vested interest in maximising the benefits of their participation. By requiring this co-investment, MAGS strikes a balance, allowing limited government funds to stretch further while still significantly alleviating financial barriers for businesses.
Beyond the practical support MAGS offers, the benefits of attending international conferences like AusBiotech extend to establishing WA’s place in a rapidly expanding industry. Conferences such as these create forums for networking and knowledge-sharing, where businesses can showcase their innovations, exchange ideas, and discuss challenges with industry peers from around the world. This visibility is crucial for the WA sector as it works to keep pace with global developments, with AusBiotech covering topics from cutting-edge research and new technologies to market access strategies. The conference also sets the stage for discussions on the latest regulatory shifts, providing WA companies with valuable insights into the requirements for bringing their innovations to different markets.
Several WA companies are making waves at this year’s AusBiotech event, with names like BlinkLab and Neurotologix set to present at the AusBioInvest conference, a prominent precursor to AusBiotech. These companies are leading examples of WA’s strengths in neuroscience and bioengineering, respectively, and their presentations highlight the type of groundbreaking work coming out of the state. Other participants, including Lixa, iyarn, and the Perron Institute, are all at the forefront of the state’s life sciences scene. By creating a designated WA booth on the conference floor, the state ensures that the delegation will have a centralised hub for networking and knowledge exchange. Supported by both state departments, this presence acts as an anchor for WA companies to direct interested parties, while also promoting WA’s biomedical capabilities as a whole.
The importance of supporting local biomedical companies extends beyond their immediate success; it is about enhancing the state’s reputation and creating an ecosystem that fosters innovation, research, and collaboration. In recent years, the WA government has invested in both policy and funding initiatives designed to increase the state’s competitiveness in various fields, including the life sciences. By encouraging the sector’s growth, these initiatives aim to create high-skilled jobs, attract investment, and ultimately improve health outcomes for Western Australians. Minister Dawson has emphasised the importance of showcasing the talent within WA’s biomedical industry, stressing that these companies have the potential to change lives and advance healthcare, not just locally, but on a global scale.
The role of MAGS within this broader framework is to offer WA companies a “stepping stone” into the competitive global life sciences market. While the grants themselves are modest compared to the scope of some larger funding programmes, they offer crucial initial support that can have a lasting impact. For instance, many biomedical innovations require substantial funding for research and development, regulatory approval, and market launch. Without early exposure to investors and international partners, WA companies might struggle to access the resources they need to bring their products to market. Programmes like MAGS help bridge that gap, allowing innovators to connect with industry leaders and attract early interest in their products and technologies.
WA’s focus on building a strong, competitive biomedical sector aligns with similar initiatives across Australia, as all states work to capitalise on the growth potential of life sciences. Victoria, for example, has invested heavily in life sciences infrastructure and development, positioning itself as a national leader in biomedical innovation. However, WA’s approach, which includes targeted grants like MAGS and strategic support for key events, is distinctive in its efforts to create a cohesive, supportive network for biomedical startups and small businesses. By creating this structure, WA can foster a distinct life sciences ecosystem that emphasises the unique contributions of its companies and research institutions, allowing the state to stand out within the broader national landscape.
Looking ahead, the long-term impact of MAGS and similar initiatives will likely be measured in the success stories that emerge from WA’s biomedical sector. The current round of funding, with its emphasis on international market access and networking, is expected to create new opportunities for collaboration and growth. By enabling WA companies to attend events like AusBiotech, the programme not only assists individual companies but also contributes to the collective visibility and reputation of the sector. As WA’s biomedical industry continues to expand, this visibility is essential in attracting investors, researchers, and potential partners who can further drive the sector’s development.
The potential of WA’s biomedical sector lies not just in its current successes but in its capacity for future growth. As more WA companies access international markets and build networks through programmes like MAGS, the industry’s profile will undoubtedly rise, bringing increased opportunities for investment and collaboration. The Cook Government’s ongoing support demonstrates a commitment to fostering an environment where innovation can thrive, with WA’s health and medical life sciences sector positioned as a key driver of both economic growth and societal benefit.
For businesses, researchers, and investors, WA’s biomedical landscape is a dynamic and promising field with significant untapped potential. Through focused funding and strategic participation in global industry events, the state is laying the groundwork for a resilient and innovative life sciences sector that can contribute meaningfully to both the local and global stage. By supporting these companies today, WA is investing in a future where its biomedical innovations can lead to tangible improvements in healthcare, positioning the state as a significant player in the global life sciences arena.
Support independent community journalism. Support The Indian Sun.
Follow The Indian Sun on X | Instagram | Facebook
Support Independent Community Journalism
Dear Reader,The Indian Sun exists for one reason: to tell stories that might otherwise go unheard.
We report on local councils, state politics, small businesses and cultural festivals. We focus on the Indian diaspora and the wider multicultural community with care, balance and accountability. We publish in print and online, send regular newsletters and produce video content. We also run media training programs to help community organisations share their own stories.
We operate independently.
Community journalism does not have the backing of large media corporations. Advertising revenue fluctuates. Platform algorithms change. Costs continue to rise. Yet the need for credible, grounded reporting in a multicultural Australia has never been greater.
When you support The Indian Sun, you support:
• Independent reporting on issues affecting migrant communities
• Coverage of local and state decisions that shape daily life
• A platform for small businesses and community groups
• Media training that builds skills within the community
• Journalism accountable to readers
We cannot cover everything, but we work to cover what matters.
If you value thoughtful reporting that reflects Australia’s diversity, we invite you to contribute. Every donation helps us maintain the quality and consistency of our work.
Please consider making a contribution today.
Thank you for your support.
The Indian Sun Team
